Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
Status:
Active, not recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, non-randomised, open-label, multicentric study to investigate the efficacy
and safety of pembrolizumab monotherapy in 7 cohorts of patients with specific rare cancers
who have unresectable locally advanced or metastatic disease, which is resistant or
refractory to standard therapy, or for which standard therapy does not exist, or is not
considered appropriate, and for which no other experimental treatment options are available,
in order to identify subsets of patients that may benefit from treatment
Phase:
Phase 2
Details
Lead Sponsor:
UNICANCER
Collaborators:
Ligue contre le cancer, France Merck Sharp & Dohme Corp. National Cancer Institute, France